key: cord-0853442-mhor9pjg
authors: Malin, Jakob J.; Di Cristanziano, Veronica; Horn, Carola; Pracht, Elisabeth; Borrega, Jorge Garcia; Heger, Eva; Knops, Elena; Kaiser, Rolf; Böll, Boris; Lehmann, Clara; Jung, Norma; Borchmann, Peter; Fätkenheuer, Gerd; Klein, Florian; Hallek, Michael; Rybniker, Jan
title: SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma
date: 2021-12-18
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006655
sha: 40b1f2d2d07fb4d057e673ebd47bfd68ac4d54a4
doc_id: 853442
cord_uid: mhor9pjg

Humoral immunodeficiency is a common finding in patients with B-cell related malignancies such as Non-Hodgkin lymphoma. Failure to induce a sufficient humoral immune response to viral pathogens such as SARS-CoV-2 can result in impaired viral clearance with prolonged viral shedding and symptomatic infections. Here we describe six COVID-19 patients with B-cell Non-Hodgkin lymphoma and impaired humoral immune response that were successfully treated with SARS-CoV-2 neutralizing monoclonal antibodies (nMABs) between June and October 2021. Patients exhibited serological vaccination failure or were unable to clear SARS-CoV-2 even after prolonged infections. Two patients presented with persistent COVID-19 for more than three months. One patient suffered from a third episode of COVID-19 despite vaccination and one patient was diagnosed by SARS-CoV-2 viremia and a positive PCR from the lower respiratory tract while subsequent nasopharyngeal swabs remained negative. In the six described cases, passive immunization with nMABs resulted in rapid and sustained clinical improvement and decrease in viral loads. SARS-CoV-2 nMABs provide a highly attractive treatment option for COVID-19 patients unable to mount a humoral immune response following vaccination or infection.

The adaptive humoral immune response to SARS-CoV-2 plays a critical role to establish protective 23 immunity after infection or vaccination. [1] [2] [3] Viral clearance and immunological control seems to be 24 affected in patients with humoral deficiency that can present with persistent viral shedding and pro-25 longed COVID-19. 4-8 Impaired adaptive immunity due to dysfunctional or depleted B-cells and hy-26 pogammaglobinemia are common features in B-cell related malignancies such as B-cell Non-Hodgkin 27 lymphomas (B-NHL). 9-12 Due to the inability to mount sufficient amounts of SARS-CoV-2 neutralizing 28 antibodies, those patients are at risk for prolonged COVID-19 7,8 and vaccination failure. 13, 14 Passive 29 immunization with SARS-CoV-2 neutralizing monoclonal antibodies (nMABs) demonstrated beneficial 30 effects on mortality, clinical course and viral load in immunocompetent unvaccinated patients with 31 mild disease that were treated early 15-17 and prior to endogenous IgG production (IgG-32 seronegative). 18 . These trials did not focus on patients with immunosuppression or cancer. However, 33 the results suggest that induction of humoral immune response several days after symptom onset 34 marks a critical barrier for treatment efficacy. Thus, passive immunization with nMABs may be a ra-35 tional treatment approach for patients unable to produce sufficient amounts of endogenous neutral-36 izing antibodies following vaccination or infection irrespective of symptom duration. Here, we give a 37 detailed description of hospitalized COVID-19 patients with impaired humoral immunity due to un-38 derlying B-NHL that were successfully treated with nMABs in the context of an individual healing 39 attempt. 40

During June to October 2021, six consecutive patients (median age 59.5; range 39-78) were included 41 in our study (Table 1 ; see supplementary methods for a description of the process). All patients had 42 known hypogammaglobinemia, five had received B-cell depleting therapy and four of them received 43 regular prophylactic intravenous or subcutaneous immunoglobulin substitutions. All patients had 44 detectable viremia and symptomatic SARS-CoV-2 infection (WHO progression scale 4-6) with fever, 45 myalgia and malaise. Respiratory symptoms and radiologic signs of pulmonary manifestation were 46 detectable, however, none of the patients required mechanical ventilation throughout the observed 47 period. Patients gave written informed consent for scientiffic evaluation. The study was approved by 48 the local ethics committee of the University Hospital of Cologne. 49

Two unvaccinated patients (patient A and patient B) presented with persisting COVID-19 over more 50 than three months including persistent viral shedding (first positive PCR was 86 and 63 days before 51 nMAB treatment), viremia, recurrent fever episodes and respiratory symptoms. Despite prolonged 52 disease both patients had non-detectable SARS-CoV-2-specific IgG. Patient A was under anti-CD20 53 maintenance therapy with obinutuzumab for follicular lymphoma. The initial detection of SARS-CoV-tomatic disease and presented at a secondary referral hospital. Despite treatment with anti-infective 56 agents and dexamethasone, he showed progressive respiratory distress and was transferred to our 57 intensive care unit for high-flow oxygen therapy where the respiratory situation stabilized during the 58 next days. Although respiratory improvement was achieved we observed recurrent fever episodes 59 with persistent viral shedding and viremia so that treatment with nMABs was initiated. including the initial screening assessment remained negative (Supplemental Figure 1) . No other 91 pathogens were detected in blood or BAL samples. 92

All patients were treated with one intravenous dose of 1200/1200 mg casirivimab/imdevimab. Fol-93 lowing infusion, we observed a rapid and significant clinical improvement during the following days. 94

Fever abated within the first 48 hours and CRP improved rapidly from the second day after treatment 95 for those with marked elevation > 50 mg/L (4/6 patients, Figure 1 ). Respiratory viral loads reduced 96 from median 4.5 x 10 5 copies/mL pre-treatment (day -2 to day 0) to 1 x 10 3 copies/mL in the post- The data used and analyzed will be provided by the corresponding author (jan.rybniker@uk-125 koeln.de) on reasonable request and in agreement with protection of data privacy. 

load before and after nMAB treatment. Individual evolution of temperature (A) and C-reactive pro-184 tein (B) from two days before (day -2) until five days after (day 5) nMAB treatment (day 0). SARS-185

CoV-2 RNA was determined by quantitative RT-PCR and CT values were translated to viral concentra-186 tions based on the respective PCR core standards. Viral loads obtained from respiratory tract speci-187 men (C) and blood (D) before and after nMAB treatment are presented cumulative and may repre-188 sent samples taken from 2 days before until midday at the day of nMAB treatment (pre-treatment) 189

or samples from day 1 until day 5 after treatment (post-treatment). If several samples were taken 190 during these time periods the median from all available assessments is shown for each patient. Pa-191 tient F is not included in section C as only samples obtained from BAL were positive and no subse-192 quent assessment were performed. CRP indicates C-reactive protein; FU, follow up; and ND, not de-193 tected. 194

Adaptive immune determinants of viral clearance and 140 protection in mouse models of SARS-CoV-2. bioRxiv

Covid-19 Breakthrough Infections in Vaccinated Health 142 Care Workers

BNT162b2 vaccine breakthrough: 144 clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical 145 Microbiology and Infection

Persistent COVID-19 in an Immunocompromised 147 Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Case Study: Prolonged Infectious SARS-CoV-2 150 Shedding from an Asymptomatic Immunocompromised Individual with

Persistence and Evolution of SARS-CoV-2 in an 153 Immunocompromised Host

Convalescent plasma therapy for B-cell-depleted patients 155 with protracted COVID-19

COVID-19 in Patients Receiving CD20-depleting 157 Immunochemotherapy for B-cell Lymphoma

Rituximab treatment results in impaired 159 secondary humoral immune responsiveness

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and 161 impaired B-cell reconstitution

Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A 163 Predictor of Outcome?

Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia 165 and Challenges during COVID-19 Pandemic

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in 167 patients with chronic lymphocytic leukemia

Poor Neutralizing Antibody Responses in 132 169 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. 170 Cancers (Basel)

REGEN-COV Antibody Cocktail Clinical 172 Outcomes Study in Covid-19 Outpatients. medRxiv

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-174 19

Casirivimab and imdevimab in patients admitted to hospital 177 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv

BAU/ml = negative

‡ Live Virus Neutralization Test (VNT) demonstrated poor neutralizing activity (100% inhibitory dilution/ID100 of 10)